Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
26.81
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
A Closer Look at 5 Analyst Recommendations For Beam Therapeutics
August 22, 2024
Via
Benzinga
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
August 14, 2024
William Blair initiates coverage on Korro Bio highlighting its innovative RNA editing platform, ADAR-based OPERA. The analyst rates the stock Outperform, noting its potential in treating alpha-1...
Via
Benzinga
3 Gene Editing Stocks with Potential to Transform Medicine
August 09, 2024
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.
Via
InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q2 2024
August 06, 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
August 06, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Expert Ratings For Beam Therapeutics
April 23, 2024
Via
Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
July 28, 2024
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%
Via
Benzinga
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday
July 25, 2024
Via
Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
July 24, 2024
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.
Via
Investor's Business Daily
Why Is Conn’s (CONN) Stock Down 36% Today?
July 24, 2024
Conn’s stock is falling on Wednesday as CONN investors react to reports of potential store closures and a bankruptcy filing.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40
July 24, 2024
Beam Therapeutics recently got a vote of confidence from a Wall Street analyst, providing fuel for further upside in BEAM stock.
Via
InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
July 23, 2024
Via
Benzinga
3 Gene Editing Stocks Shaping the Future of Medicine
July 22, 2024
Gene editing stocks offer a bold venture into biopharma's future, leveraging CRISPR technology for transformative healthcare solutions
Via
InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
July 18, 2024
Via
Benzinga
Beam Therapeutics Announces Transition of Chief Financial Officer
July 15, 2024
From
Beam Therapeutics
Via
GlobeNewswire
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
July 09, 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge.
Via
InvestorPlace
3 Stocks With the Potential to 10X Your Money
July 09, 2024
These three top high-growth potential stocks could offer substantial growth and give your portfolio a major boost.
Via
InvestorPlace
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
July 03, 2024
These high-risk, high-reward stocks have the potential to turn $1K into $1M by 2030, according to Amazon-backed AI Claude 3.5 Sonnet.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
June 27, 2024
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.
Via
InvestorPlace
Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
June 26, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
June 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
May 30, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
May 14, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
May 08, 2024
From
Beam Therapeutics
Via
GlobeNewswire
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
May 07, 2024
From
Beam Therapeutics
Via
GlobeNewswire
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO:
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.